Personalis Pre-Tax Profit Margin 2018-2026 | PSNL
Personalis pre-tax profit margin from 2018 to 2026. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
| Personalis Pre-Tax Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Pre-Tax Income | Pre-Tax Margin |
| 2026-06-30 | $0.07B | $-0.11B | -158.82% |
| 2026-03-31 | $0.06B | $-0.10B | -152.38% |
| 2025-12-31 | $0.07B | $-0.08B | -118.84% |
| 2025-09-30 | $0.07B | $-0.07B | -107.25% |
| 2025-06-30 | $0.08B | $-0.09B | -112.35% |
| 2025-03-31 | $0.09B | $-0.08B | -96.55% |
| 2024-12-31 | $0.09B | $-0.08B | -94.19% |
| 2024-09-30 | $0.09B | $-0.09B | -103.37% |
| 2024-06-30 | $0.08B | $-0.08B | -101.23% |
| 2024-03-31 | $0.08B | $-0.09B | -124.00% |
| 2023-12-31 | $0.07B | $-0.11B | -147.30% |
| 2023-09-30 | $0.07B | $-0.11B | -159.15% |
| 2023-06-30 | $0.07B | $-0.11B | -161.76% |
| 2023-03-31 | $0.07B | $-0.11B | -165.22% |
| 2022-12-31 | $0.07B | $-0.11B | -173.85% |
| 2022-09-30 | $0.07B | $-0.10B | -147.83% |
| 2022-06-30 | $0.08B | $-0.09B | -123.68% |
| 2022-03-31 | $0.08B | $-0.08B | -101.25% |
| 2021-12-31 | $0.09B | $-0.07B | -75.58% |
| 2021-09-30 | $0.09B | $-0.06B | -68.24% |
| 2021-06-30 | $0.08B | $-0.05B | -60.24% |
| 2021-03-31 | $0.08B | $-0.04B | -55.00% |
| 2020-12-31 | $0.08B | $-0.04B | -52.56% |
| 2020-09-30 | $0.08B | $-0.04B | -46.05% |
| 2020-06-30 | $0.07B | $-0.03B | -43.84% |
| 2020-03-31 | $0.07B | $-0.03B | -41.43% |
| 2019-12-31 | $0.07B | $-0.03B | -40.00% |
| 2019-06-30 | $0.04B | $-0.02B | -38.10% |
| 2019-03-31 | $0.04B | $-0.02B | -48.57% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.687B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |